Glycophos

Glycophos is a prescription intravenous product whose active ingredient is sodium glycerophosphate pentahydrate. It is supplied in a sterile solution for injection, with the specific strength not publicly disclosed. The preparation is manufactured for the European market and is intended for use under the supervision of a qualified healthcare professional. It may be used in clinical settings where phosphate supplementation is required, and it is stored according to pharmaceutical guidelines.

Glycophos is administered intravenously when a rapid increase in serum phosphate levels is clinically indicated, particularly in hospital environments such as intensive care units or during major surgical procedures.

- Treatment of documented hypophosphatemia to restore normal phosphate concentrations. - Supplementation of phosphate in patients receiving continuous renal replacement therapy who are at risk of depletion. - Inclusion in parenteral nutrition regimens to provide essential phosphate for metabolic processes. - Management of refeeding syndrome where rapid phosphate shifts can occur after nutritional rehabilitation. - Correction of electrolyte imbalances during major surgery or trauma care when phosphate loss is anticipated.

Intravenous administration of sodium glycerophosphate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Mild elevation of serum phosphate that typically resolves without additional treatment. - Transient decrease in calcium levels, which may cause mild tingling or paresthesia. - Nausea or mild gastrointestinal discomfort such as stomach upset. - Local irritation, erythema, or pain at the infusion site during or after administration.

Serious: - Marked hyperphosphatemia that can lead to calcium‑phosphate precipitation and tissue calcification. - Metabolic acidosis resulting from an excessive phosphate load, potentially requiring corrective measures. - Severe hypersensitivity reactions, including rash, bronchospasm, or anaphylaxis, necessitating immediate medical intervention.

When using Glycophos, clinicians should observe specific precautions to minimize risks and ensure safe administration.

- Verify baseline serum phosphate and calcium concentrations before initiating therapy. - Continuously monitor electrolyte levels, especially phosphate, calcium, and magnesium, throughout the infusion. - Reduce or adjust the dose in patients with impaired renal function or severe kidney disease. - Infuse the solution at the recommended rate to prevent sudden shifts in phosphate balance. - Ensure compatibility with other intravenous medications and avoid mixing in the same line unless stability is confirmed. - Follow strict aseptic technique during preparation and administration to prevent infection.

Sodium glycerophosphate may interact with certain medications or clinical conditions; awareness of these interactions helps guide safe co‑administration.

Avoid: - Concurrent infusion of calcium salts or calcium‑containing solutions, which can precipitate calcium‑phosphate crystals. - Administration together with other phosphate‑rich intravenous fluids, increasing risk of hyperphosphatemia. - Use in patients with untreated severe hyperphosphatemia, as it may exacerbate the condition.

Use with caution: - Co‑administration with loop or thiazide diuretics that alter calcium and phosphate balance; monitor electrolytes closely. - Concurrent use of vitamin D analogues or calcitriol, which can affect calcium‑phosphate homeostasis. - Patients receiving anticoagulant therapy, particularly warfarin, may require monitoring of calcium‑dependent clotting factors.